Page 25 - Complete Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data WASHINGTON (dpa-AFX) - Today's Daily Dose brings you news about BioCryst's update on its investigational broad-spectrum antiviral Galidesivir in the treatment of COVID-19, a $7 million strategic investment by Acorn Bioventures in Cyclacel Pharma, Supernus' phase III study results of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder, and Spectrum's progress with Poziotinib for non-small cell lung cancer. Read on. 1. BioCryst Not to Pursue COVID-19 indication for antiviral G...

December 21, 2020 --Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population - -- Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly Bortezomib Combination Regimen - -- First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 - -- FDA Approval Comes Approximately Three Months Ahead of Target PDUFA Date - SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ -- Antengene C...